Could a single dose of pneumococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination

Ezra J. Barzilay; Katherine L. O'Brien; Yeong S. Kwok; Robert M. Hoekstra; Elizabeth R. Zell; Raymond Reid; Mathuram Santosham; Cynthia G. Whitney; Daniel R. Feikin

doi:10.1016/j.vaccine.2005.08.092

Could a single dose of pneumococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination

Ezra J. Barzilay, Katherine L. O'Brien, Yeong S. Kwok, Robert M. Hoekstra, Elizabeth R. Zell, Raymond Reid, Mathuram Santosham, Cynthia G. Whitney, Daniel R. Feikin

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Using incidence rates from CDC's Active Bacterial Core surveillance and immunogenicity data from the Navajo/Apache trial of pneumococcal conjugate vaccine (PCV), we used Markov modeling to predict the optimal age to give a single dose of PCV. Antibody concentration thresholds of 0.35 and 1.0 mcg/ml were considered protective. Our outcome was vaccine serotype-specific invasive pneumococcal disease (IPD) incidence at 24 months. The models predicted the optimal age to vaccinate is 5-7 months with vaccine-induced immunologic memory and 8-10 months without memory. IPD reduction ranged from 15 to 62%, depending on model parameters. A single PCV dose in infants could prevent substantial IPD.

Original language	English (US)
Pages (from-to)	904-913
Number of pages	10
Journal	Vaccine
Volume	24
Issue number	7
DOIs	https://doi.org/10.1016/j.vaccine.2005.08.092
State	Published - Feb 13 2006

Keywords

Markov model
Pneumococcal conjugate vaccine
Reduced dose vaccination model

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2005.08.092

Cite this

@article{8b9a0311909840febc3b9829f8b44a9f,

title = "Could a single dose of pneumococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination",

abstract = "Using incidence rates from CDC's Active Bacterial Core surveillance and immunogenicity data from the Navajo/Apache trial of pneumococcal conjugate vaccine (PCV), we used Markov modeling to predict the optimal age to give a single dose of PCV. Antibody concentration thresholds of 0.35 and 1.0 mcg/ml were considered protective. Our outcome was vaccine serotype-specific invasive pneumococcal disease (IPD) incidence at 24 months. The models predicted the optimal age to vaccinate is 5-7 months with vaccine-induced immunologic memory and 8-10 months without memory. IPD reduction ranged from 15 to 62%, depending on model parameters. A single PCV dose in infants could prevent substantial IPD.",

keywords = "Markov model, Pneumococcal conjugate vaccine, Reduced dose vaccination model",

author = "Barzilay, {Ezra J.} and O'Brien, {Katherine L.} and Kwok, {Yeong S.} and Hoekstra, {Robert M.} and Zell, {Elizabeth R.} and Raymond Reid and Mathuram Santosham and Whitney, {Cynthia G.} and Feikin, {Daniel R.}",

year = "2006",

month = feb,

day = "13",

doi = "10.1016/j.vaccine.2005.08.092",

language = "English (US)",

volume = "24",

pages = "904--913",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "7",

}

TY - JOUR

T1 - Could a single dose of pneumococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination

AU - Barzilay, Ezra J.

AU - O'Brien, Katherine L.

AU - Kwok, Yeong S.

AU - Hoekstra, Robert M.

AU - Zell, Elizabeth R.

AU - Reid, Raymond

AU - Santosham, Mathuram

AU - Whitney, Cynthia G.

AU - Feikin, Daniel R.

PY - 2006/2/13

Y1 - 2006/2/13

N2 - Using incidence rates from CDC's Active Bacterial Core surveillance and immunogenicity data from the Navajo/Apache trial of pneumococcal conjugate vaccine (PCV), we used Markov modeling to predict the optimal age to give a single dose of PCV. Antibody concentration thresholds of 0.35 and 1.0 mcg/ml were considered protective. Our outcome was vaccine serotype-specific invasive pneumococcal disease (IPD) incidence at 24 months. The models predicted the optimal age to vaccinate is 5-7 months with vaccine-induced immunologic memory and 8-10 months without memory. IPD reduction ranged from 15 to 62%, depending on model parameters. A single PCV dose in infants could prevent substantial IPD.

AB - Using incidence rates from CDC's Active Bacterial Core surveillance and immunogenicity data from the Navajo/Apache trial of pneumococcal conjugate vaccine (PCV), we used Markov modeling to predict the optimal age to give a single dose of PCV. Antibody concentration thresholds of 0.35 and 1.0 mcg/ml were considered protective. Our outcome was vaccine serotype-specific invasive pneumococcal disease (IPD) incidence at 24 months. The models predicted the optimal age to vaccinate is 5-7 months with vaccine-induced immunologic memory and 8-10 months without memory. IPD reduction ranged from 15 to 62%, depending on model parameters. A single PCV dose in infants could prevent substantial IPD.

KW - Markov model

KW - Pneumococcal conjugate vaccine

KW - Reduced dose vaccination model

UR - http://www.scopus.com/inward/record.url?scp=31844436976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31844436976&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.08.092

DO - 10.1016/j.vaccine.2005.08.092

M3 - Article

C2 - 16203059

AN - SCOPUS:31844436976

SN - 0264-410X

VL - 24

SP - 904

EP - 913

JO - Vaccine

JF - Vaccine

IS - 7

ER -

Could a single dose of pneumococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this